Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current assets    
Cash $ 26,407 $ 14,305
Prepaid expenses 5,964
Total current assets 32,371 14,305
Total Assets 32,371 14,305
Current liabilities    
Accounts payable 352,264 349,849
Accrued interest payable 293,639 302,834
Notes payable - current - related parties 592,350 627,022
Notes payable - current, net 163,574 163,574
Derivative liability 539,327 180,038
Stock subscription payable 53,081 28,081
Related party payables 1,166,799 1,111,754
Other payables 290,532 263,033
Total current liabilities 3,451,566 3,026,185
Total Liabilities 3,451,566 3,026,185
Stockholders' Deficit    
Preferred stock
Common stock, $.00001 par value; 100,000,000 shares authorized; 100,000,000 and 67,751,068 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively 1,000 677
Additional paid in capital 14,176,591 14,095,430
Accumulated deficit (17,551,920) (17,064,086)
Total Transbiotec, Inc. stockholders' deficit (3,374,329) (2,967,979)
Noncontrolling interest (44,866) (43,901)
Total Stockholders' Deficit (3,419,195) (3,011,880)
Total Liabilities and Stockholders' Deficit 32,371 14,305
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock